Futura Medical PLC Posting of Circular and Notice of General Meeting (8896Y)
17 Mayo 2021 - 9:08AM
UK Regulatory
TIDMFUM
RNS Number : 8896Y
Futura Medical PLC
17 May 2021
17 May 2021
Futura Medical plc
("Futura" or the "Company")
Posting of Circular and Notice of General Meeting
Further to the Company's announcement of 17 May 2021, that it
has conditionally raised GBP12 million before fees and expenses by
way of a Placing and Retail Offer with certain existing
institutional and other investors, Futura confirms that the
Circular (containing a notice convening the General Meeting) has
been posted to Shareholders and will shortly be available for
download on the Company's website:
https://www.futuramedical.com
Comple tion of the Fundraising is conditional, inter alia, upon
Shareholder approval of the Resolutions to be proposed at a general
meeting of the Company, expected to be held at the offices of
Futura Medical plc at Surrey Technology Centre, 40 Occam Road,
Guildford, Surrey GU2 7YG at 10:00 a.m. on 2 June 2021.
The ongoing Government restrictions on mass gatherings,
non-essential travel and social contact in relation to COVID are
likely to impact the ability of Shareholders to attend the General
Meeting. Based on current restrictions, the Board has concluded
that it is appropriate to strongly urge shareholders not to attend
the General Meeting in person this year. Shareholders are instead
requested to make use of the electronic facilities detailed below
and to vote remotely.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 20 3922 0900
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZGMKDNNGMZM
(END) Dow Jones Newswires
May 17, 2021 10:08 ET (14:08 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024